Watch CBSN Live

What's Next In Martha Trial?

When the Martha Stewart trial resumes in New York this morning, it's not clear who will be called to the stand.

A ruling by the judge last week delayed the testimony of the government's star witness until Thursday at the earliest. Forced to present their case out of order, prosecutors have spent an anxious weekend deciding who's next.

A former assistant to Stewart's broker, Douglas Faneuil is expected to tell the jury that his boss and Stewart sold Stewart's shares in Imclone Systems after an illegal tip.

But a document that surfaced last week casts doubt on Faneuil's story. The defense was given a week to examine the document.

The delay came after doubts were raised about what Faneuil's former lawyer recalled about the circumstances of the stock sale that triggered the case against Stewart.

Faneuil is the former brokerage assistant at Merrill Lynch & Co. who sold Stewart's 3,928 shares of ImClone Systems stock in 2001 on orders from Stewart.

"He's the linchpin of the State's case," Court TV's Nancy Grace, a former prosecutor, said of Faneuil to CBS News Correspondent Sharyn Alfonsi.

The government says Stewart sold the shares because her stockbroker and co-defendant, Peter Bacanovic, sent a tip through Faneuil that ImClone Systems founder Sam Waksal was trying to dump his family's shares.

But Faneuil's former lawyer, Jeremiah Gutman, gave a statement to the FBI in 2003 that raised questions about whether it was Bacanovic or Waksal who had ordered Faneuil to tip off Stewart.

In court Thursday, defense attorneys suggested Faneuil had told his lawyer he was not sure whether it was Bacanovic or Waksal. The government suggested it was Gutman - who is in his 80s - who had the memory problem.

It was not immediately clear why prosecutors turned over Gutman's FBI statement late Wednesday night. Lawyers for Stewart and Bacanovic said it should have been provided to them long ago.

"I do think the government should have turned over this information sooner," U.S. District Judge Miriam Goldman Cedarbaum said.

Faneuil had been scheduled to testify Thursday, but Cedarbaum postponed the testimony indefinitely. When prosecutors could not arrange for another witness to come in ahead of schedule in Faneuil's place, she called the trial off for the week. It had already skipped a day Wednesday because of a snowstorm

Defense attorneys want at least a week to investigate Gutman's statement to the FBI in 2003, as well as Gutman's discussions with Faneuil in January 2002.

Gutman himself, who no longer serves as Faneuil's lawyer, has declined to be interviewed by defense attorneys.

"The government knows what its obligations are," Stewart attorney Robert Morvillo told the judge. "The government has failed to fulfill their obligation with respect to Mr. Faneuil."

The government claims it did not violate any trial rules, and that it was sufficient just to tell the defense that Gutman was part of their case — not what he specifically recalled.

"For Mr. Morvillo to claim there's a Brady violation here is disingenuous," prosecutor Karen Patton Seymour said, referring to a trial rule that requires prosecutors to share some information about witnesses with the defense.

Bacanovic lawyer Richard Strassberg first asked the judge to throw out the indictment against his client, then asked her to declare a mistrial. The judge denied both requests.

Also Thursday, Cedarbaum said she would consider a request from Stewart's attorneys to question Faneuil "about drug use," but asked the defense to produce documents backing up its request. The judge did not elaborate.

Just after Stewart sold the stock on Dec. 27, 2001, a negative government report about an ImClone cancer drug sent the stock tumbling. Waksal later admitted he had advance knowledge of the report.

Stewart and Bacanovic are accused of cooking up a false story about why Stewart sold the stock that day. They claim they had a pre-existing agreement to sell ImClone when it fell to $60 per share.

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.